Loading patent…
AssigneesNational Cancer Center, Miraca Research Institute G.K.
InventorsHirofumi MUKAI, Toshikazu USHIJIMA, Satoshi YAMASHITA
Estimating the term…
The present invention provides a factor capable of predicting an effect of a medicinal therapy on a cancer such as HER2 positive cancer. More specifically, the present invention provides a method of predicting the effect of the medicinal therapy on the cancer, comprising: (1) analyzing a methylation level of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene in a sample taken from a human subject; and (2) predicting the effect of the medicinal therapy on the cancer based on the analyzed methylation level.
A method of predicting an effect of a medicinal therapy on a cancer, the method comprising:
A diagnosis kit for an effect of a medicinal therapy on a cancer, the diagnosis kit comprising an analytical means for analyzing methylation of a cytosine residue in one or more CpG sites present within a nucleotide sequence in a promotor region, an untranslated region or a translated region of HSD17B4 gene.
A medicinal therapy on a cancer, comprising:
A method of selecting a treatment on a cancer, comprising:
Dependencies are inferred from the claim text.